[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psychiatric-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psychiatric-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,41,73,163,186,218,241,272,319,345,366,386,414,435,459,479,508,537,557,581,602,690,713,737,764],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100583136","medical-comorbidities-in-bipolar-disorder-100583136",false,"NCT06872398","Medical Comorbidities in Bipolar Disorder","Medical Comorbidities in Bipolar Disorder : Clinical Validation of Risk Factors and Biomarkers to Improve Prevention and Treatment;","BIPCOM","Inclusion Criteria:\n\n* Primary diagnosis of BP I, BP II, or BP NOS\n* Have had at least one contact with mental health services in the past year\n* Be aged between 18 and 65 years old\n* Have signed an informed consent\n\nExclusion Criteria:\n\n* Projected move within the next year.\n* Severe psychiatric comorbidities (schizophrenia spectrum disorders).\n* Severe cognitive impairment.\n* Severe substance or alcohol abuse: quantified by specific scores on the AUDIT and DAST.","ALL","18 Years","65 Years",{"count":22,"type":23},80,"ESTIMATED","OBSERVATIONAL","Bipolar Disorder (BD) is a common, heritable, chronic, and recurrent disorder that represents a critical public health problem, due to its prevalence, its high degree of disability and psychiatric and MC (MC): these represent a significant additive burden for BD patients, with a large clinical heterogeneity and an urgent need for personalised treatment and management. BIPCOM overarching purpose is to study MC in people with BD and to improve diagnostic and treatment outcomes with a precision medicine approach targeting 3 objectives: (1) to identify prevalence rates, risk and protective factors and natural history of MC among subjects with BD, through analyses of the Nordic biobanks and medical registers Work Package WP(WP2) and a cross- sectional study exploiting existing datasets of patients with BD (WP3); (2) to conduct an Exploratory Clinical Study (ECS - WP4) involving 400 subjects (80 X 5 recruiting sites), to assess the overall clinical profile of these patients and quantify the 1-year incidence of specific risk factors for the onset of metabolic syndrome (MetS) (WP5); (3) to develop a Clinical Support Tool (CST), including a set of recommendations, to support individualized clinical decision-making in BD comorbidity management and improve prevention, early detection and effective treatment, while ensuring the translation of project results' into clinical practice (WP5 and 6). BIPCOM will be implemented through continuous consultations with stakeholders (scientific and patients' associations, users and families), for ensuring results' acceptability and transferability. The successful implementation of the project will have a significant impact upon the general health of people with BD, eventually leading to lower mortality rates and reduced incidence of severe disabilities, whilst providing reliable methods and tools for patients' stratification and personalized treatments.",[27],"Psychiatric Disorder","RECRUITING","2026-10-06",{"date":31,"type":32},"2026-10-07","ACTUAL",{"date":34,"type":32},"2024-10-11",{"date":36,"type":23},"2026-12",{"name":38,"class":39},"Fondation FondaMental","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100631214","a-brief-case-management-intervention-to-promote-personal-recovery-and-prevent-psychiatric-involuntary-readmissions-100631214","NCT07497763","A Brief Case Management Intervention to Promote Personal Recovery and Prevent Psychiatric Involuntary Readmissions.","A Brief Case Management Intervention to Promote Personal Recovery and Prevent Psychiatric Involuntary Readmissions: a Randomised Controlled Trial","CARP-RCT","Inclusion Criteria:\n\n* To have been involuntarily admitted by a medical doctor;\n* To be aged between 18 and 64 years;\n* To domiciled in the Greater Lausanne area;\n\nExclusion Criteria:\n\n* Patients with an organic mental disorder (F0, ICD-10);\n* Patients with intellectual disability (F7, ICD-10);\n* Patients unable to provide written consent due to a lack of discernment;\n* Patients unable to speak French well enough to participate in the study without the help of an interpreter.","64 Years",{"count":51,"type":23},262,"INTERVENTIONAL",[54],"NA","The goal of this randomized control trial is to assess the effectiveness of a Brief Case Management (BCM) intervention aimed at promoting personal recovery and reducing the negative effects of coercion among people involuntarily admitted to a psychiatric hospital.\n\nThe main questions it aims to answer are :\n\n* Does the Brief Case Management intervention reduce the incidence of involuntary readmission18 months after the initial involuntary hospitalisation?\n* What impact does the Brief Case Management intervention have on patients' involuntary readmission 6 months after the initial involuntary hospitalisation, as well as on their personal recovery, perceived coercion, satisfaction with treatment, and on their exposure to other forms of formal and informal coercion?\n\nParticipants will be randomly assigned to either the control or the intervention group, accordingly they will be asked to take part in:\n\nControl Group:\n\n* Three evaluation sessions (baseline, 6 and 18 months follow-up);\n\nIntervention Group :\n\n* Three evaluation sessions (baseline, 6 and 18 months follow-up);\n* The 5 sessions of the brief case management intervention (6th session optional).",[27,57],"Involuntary Psychiatric Hospitalization",[59,60,61,62,63],"coercion","involuntary admission","personal recovery","case management","psychiatry","2026-09-30",{"date":66,"type":32},"2026-10-05",{"date":68,"type":32},"2026-07-01",{"date":70,"type":23},"2029-12",{"name":72,"class":39},"Stéphane Morandi",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":18,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":52,"phases":86,"briefSummary":87,"conditions":88,"keywords":132,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":40},"100641475","qaiax-aihealth4u---ai-public-health-central-microcity-a-re-quantum-ai-agency-aka-ai-city-hall-project-upsto-app-nos-64074526-64063557-63903181-63729428-100641475","NCT07661823","QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (Quantum AI\u002FAGI Agency a\u002Fk\u002Fa AI City Hall Project - UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 64\u002F105,164, 63\u002F903,181, 63\u002F729,428, 64\u002F125,360)","QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (UPSTO App No(s). 64\u002F074,526, 64\u002F063,557, 64\u002F105,164, 63\u002F903,181, 63\u002F729,428) is Frontier AI\u002FAGI Public Health Trials Sandbox Framework That Provides Free Public Health Services to Registered and Sponsored Visitors\u002FOccupants for RDT&E Under 28 U.S.C. 1498 (Classified as a PPA, OTA Under 10 U.S. Code 4001, 4022), Serving as a Global Intranet of Humans Resident Patients Among Multiple Enclave Communicates (\"AI Microcities\" or \"Smart Health Cities\") Living and Learning With AI Robotics for Non-medicinal Treatment.","QAIAx","Inclusion Criteria:\n\n* Individuals aged 17 to 99 years old.\n* Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).\n* Referral by a non-profit organization (e.g., 501c3, university, church).\n* Referral by a public agency (e.g., case manager, social worker, parole\u002Fprobation\u002FPTS officer, judge).\n\nExclusion Criteria:\n\n\\* Individuals under 17 or over 99 years of age.",true,"17 Years","99 Years",{"count":85,"type":23},1000000,[54],"BRIEF SUMMARY\n\nA. \"What is the purpose of this study?\"\n\nBACKGROUND. The QAIAx clinical trial (Quantum AI\u002FAGI Public Health Agency), known operationally as the \"AI City Hall Project,\" represents a landmark intergovernmental research initiative examining the viability of AI-governed residential ecosystems for behavioral and mental health intervention. Authorized under 10 U.S.C. 4001 (Defense Sector Research Projects, RDT\\&E) and supported by pending USPTO applications (Nos. 64\u002F074,526, 64\u002F063,557, 64\u002F105,164, 63\u002F903,181, 63\u002F729,428, 64\u002F125,360), this non-medicinal program investigates whether quantum AI-managed public administration, AI humanoid robotics, holographic holoportation (AI-119 Kikkeri Holo-Suit \u002F \"AI Wat Beam Bot\"; AI-119 Vulcan QM-Ware or \"Quasi-Mind Ware\"), and advanced AGI learning machines can reduce housing and care costs while improving mental health outcomes-particularly for persons with addiction and co-occurring psychiatric disorders.\n\nSCOPE \\& JURISDICTION. The trial operates across a network of self-contained, geodesic dome-enclosed \"Microcities\" (1,500-15,000 occupants per site) within an affiliate network of 300 communities, spanning North America, South America, Europe, Africa, Oceania, Asia, and the Middle East. Participating host nations are U.S.-allied member states party to the Status of Forces Agreement (SOFA), the Vienna Convention on Diplomatic Relations, and the Hague Convention, alongside related bilateral treaties with the U.S. government.\n\nINTERVENTION \\& POPULATION: Eligible adults (18+) reside in these Microcities for up to 36 months. Daily life-including housing, utilities, and healthcare-is administered by the ISAC AI\u002FAGI system and robots with minimal human oversight.\n\nCLINICAL TRIAL GOAL(S): The clinical trial program goals are to exemplify a sustainable AGI-managed public administration supported by AI robotics and AGI trans-human and omni-AI machines (e.g., \"Q-Men\"; \"AI-Me\"; Beam Bot\", \"QM-Ware\", \"AVK Suit\") to improve mental health outcomes-especially for those with addiction disorders-and create a financially sustainable model for people on fixed incomes or public assistance.\n\nB. \"What conditions does the study focus on?\"\n\nThe study focuses on adults with:\n\n* Autism spectrum disorders (Asperger's, autism, ADHD, ASD)\n* Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA\u002Fecstasy, tobacco\u002Fnicotine)\n* Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)\n* Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).\n\nC. \"What does the study involve?\"\n\nEligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital \"attitude inoculation\" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.\n\n\\*\\*Who can participate?\\*\\*\n\nYou may be able to join if you:\n\n* Are an adult (18 years or older)\n* Have a diagnosis of one of the listed mental-health or addiction disorders\n* Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organization (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole\u002Fprobation officer, judge)\n* Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.\n\nParticipants who are veterans, receive public assistance (e.g., VA disability, SSDI\u002FSSI, Medicaid, Medicare), or are experiencing homelessness may be prioritized.\n\n\\*\\*Where is the study taking place?\\*\\* The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.\n\n\\*\\*Who is sponsoring the study?\\*\\* The study is sponsored by Veterans Recovery Network Inc., a SCDV-owned non-profit organization, in collaboration with AI-119 Vulcan Project Research \\& Educational Technology Co. (PRETCO). The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §§§§ 4001, 4021, 4022, and 4023) and is part of a Cooperative Research and Development Agreement (CRADA) with participating segments or RDT\\&E programming missions of the United States Defense Department (DoW).\n\nThis summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.",[89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,27,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131],"Asperger's Disorder","Asperger Disorder","Autism Disorder","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","ADHD","ASD","Alcohol Abuse\u002FDependence","Alcohol Addiction","Alcohol and Other Drug Use Disorders","Alcohol and Other Substance Use Prevention","Gambling Addiction","Gambling Disorder","Sex Abuse","Sex Behavior","Sex Crimes","Sex Disorder","Sex Disorders","Gender Dysphoria, Adult","Eating Behavior Disorders","Narcotic-Related Disorders","Narcotic Addiction","Narcissism","Psychedelic Effects in Healthy Volunteers","Psychedelic Experiences","Psychedelic Drug Dependence","Marijuana Use Disorder","Marijuana Abuse and Dependence","Smoking (Tobacco) Addiction","Smoking Among Youth","Smoking Abstinence","Abstinence, Sex","Opiate Substitution Treatment","Opioid Abuse (Disorder)","Opioid Abuse and Addiction","Cocaine Abuse","MDMA ('Ecstasy')","Addiction Disorders","Homeless and Low Incomes People, Refugees","Homelessness","Reliability and Validity","Anger Problems","Child Abuse, Sexual",[133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152],"ai city hall project","ai 119","ai119","qaia","qaiax","ai wat","veterans recovery network","veterans","addiction disorder","vulcan","artificial intelligence","agi","military","sex addiction","mental health treatment","smart health cities","microcities","smartcities","smart city","omni ai","NOT_YET_RECRUITING","2026-09-14",{"date":156,"type":32},"2026-09-17",{"date":158,"type":23},"2026-09-01",{"date":160,"type":23},"2045-12-31",{"name":162,"class":39},"Veterans Recovery Network Inc.",{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":81,"sex":18,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":52,"phases":174,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":40},"100591213","electrotherapy-stimulation-together-with-life-coaching-for-the-support-of-burnout-symptoms-in-healthcare-workers-100591213","NCT06977503","Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers","A Pilot Study Using a Cranial Electrotherapy Stimulation (CES) Device in Conjunction With Life Coaching to Alleviate Burnout Symptoms in HealthCare Workers (HCWs)","Inclusion Criteria:\n\n* Age 21 ≤ and ≤ 75 years old\n* Patient-facing healthcare workers (e.g., medical doctor, advanced practice provider, nurse)\n* Experiencing symptoms of burnout, as defined by a score of 1, 2, or 3 on question #2 of the Mini-Z II Survey\n* Ability to attend three (3) in-person appointments, one (1) hour in duration, at Roswell Park at week 1, week 6 and week 15 corresponding to the initial, midpoint, and final assessments\n* Ability to use the CES daily for an hour each day\n\n  * Although the device is water-resistant, participants must agree to not use the device in the bath or shower\n* Ability to read and write in English\n* Participant has access to a computer with internet access and an email address\n\n  * Ability to attend three (3) virtual 60-minute group life coaching sessions occuring Mondays at 6:30pm EST, via Zoom\n  * Ability to complete three (3) 10-15-minute pre-recorded video assignments, which will be distributed via email (each assignment will be due by the end of the week that they are distributed)\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Subjects who self-report as pregnant or nursing. Pregnancy be verified with a urine test for all persons of childbearing potential with a uterus\n* Subjects with a self-reported history of the following: Meniere's disease, history of vertigo or prone to dizziness, seizure disorder, pacemaker \u002F implantable cardioverter-defibrillator (automatic implantable cardioverter defibrillator \\[AICD\\]), cochlear implant, or any implanted electrical devices that cannot be shut off\n* Inability to tolerate the required minimum stimulation amplitude (200 uA) during the initial device training at the baseline visit.\n* Any self-reported medical or psychiatric condition which in the PI or study physician's opinion deems the participant an unsuitable candidate to participate in this trial.\n* Unwilling or unable to follow protocol requirements","21 Years","75 Years",{"count":173,"type":23},40,[54],"This clinical trial evaluates the effect of life coaching together with Cranial Electrotherapy Stimulation (CES) as an intervention to decrease self-reported symptoms of burnout, moral distress, resilience, and employee retention in oncology healthcare workers. Burnout and moral distress are occupational hazards for oncology healthcare workers. Emotional exhaustion, depersonalization, and lack of personal accomplishment at work are symptoms of burnout. Moral distress may be defined as knowing the right thing to do but being unable to do so based upon internal or external constraints. The device is attached to the earlobes that uses cranial electrotherapy stimulation (CES) at a microcurrent to alleviate symptoms of anxiety, insomnia, pain, and possibly depression. Life coaching is partnering with clients in a thought-provoking and creative process that inspires them to maximize their personal and professional potential and can increase resiliency skills such as boundary setting and prioritizing, increases in self-compassion and self-care, and potentially indirectly positively impact patient care. Undergoing the use of CES via the CES device, coupled with life coaching, may help alleviate burnout symptoms and moral distress in oncology healthcare workers.",[27],"2026-09-03",{"date":179,"type":32},"2026-09-09",{"date":181,"type":32},"2026-02-04",{"date":183,"type":23},"2027-10-04",{"name":185,"class":39},"Roswell Park Cancer Institute",{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":52,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":214,"leadSponsor":216,"locationsCount":40},"100652329","evaluation-of-a-modularized-cognitive-behavioral-group-therapy-programme-for-young-adults-change-study-100652329","NCT07772180","Evaluation of a Modularized Cognitive Behavioral Group Therapy Programme for Young Adults (CHANGE-Study)","Feasibility and Acceptability of CHANGE (Create Health in Adolescence for New and Genuine Experiences): A Modular Cognitive Behavioral Group Psychotherapy for Young Adults With Psychiatric Disorders","CHANGE","Inclusion Criteria:\n\n1. Age \\>=18 years and \\\u003C 26 years\n2. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years, age \\>= 26 years\n2. Lack of ability to provide written informed consent\n3. Severe concomitant neurological or internal medical diseases\n4. Severe cognitive impairment (IQ \\\u003C 80, severe learning disability, brain damage or pervasive developmental disorder)\n5. Lack of eligibility for psychotherapy (e.g., insufficient language proficiency, hostile or uncooperative behavior)\n6. Acute risk of self-harm or harm to others, including acute psychosis, acute mania, or acute suicidal behavior\n7. Acute substance-based addiction","25 Years",{"count":196,"type":23},30,[54],"This prospective, non-randomised, pre-post feasibility study evaluates CHANGE, a novel 8-session modularized cognitive behavioral group psychotherapy for young adults (18-25 years) with psychiatric disorders receiving inpatient or day-care treatment. All eligible participants (planned n=30) receive the intervention in addition to treatment-as-usual; there is no control arm. The primary aim is to assess feasibility, acceptability and appropriateness of the intervention (SMI (a German scale for feasibility), SAI (a German scale for acceptability), AIS (a German scale for appropriateness) scales; recruitment, retention, adherence and dropout rates). Secondary outcomes include perceived competence, self-efficacy (SWE), motivation (FEVER), satisfaction, quality of life (WHOQOL-BREF) and level of functioning (GAF), assessed before (T0) and after (T1) the intervention.",[27],[201,202,203,204,205,206,207,208,209],"Young adults","transitional psychiatry","group psychotherapy","feasibility study","psychoeducation","suicidality","media\u002Finternet\u002Fgaming addiction","communication skills","self-efficacy","2026-08-14",{"date":212,"type":32},"2026-08-19",{"date":177,"type":23},{"date":215,"type":23},"2027-06",{"name":217,"class":39},"Max-Planck-Institute of Psychiatry",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":225,"targetDuration":227,"studyType":24,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":237,"leadSponsor":239,"locationsCount":40},"100649887","prevalence-of-brief-suicidal-crisis-in-psychiatric-settings-100649887","NCT07740356","Prevalence of Brief Suicidal Crisis in Psychiatric Settings","RBSCP","Inclusion Criteria:\n\n* Any adult patient consulting the psychiatrist in his\u002Fher office during the recruitment period, regardless of the reason for the consultation, and who has given consent to participate in this study.\n\nExclusion Criteria:\n\n* Minor patients, or patients who refuse to participate in the study.\n* Patients who have already completed the self-administered questionnaires previously (e.g., a second consultation within the same week).\n* Patients unable to understand and complete the self-administered questionnaires (cognitive impairment, difficulty understanding French, etc.).",{"count":226,"type":23},150,"1 Day","France is among the countries with one of the highest suicide rates in the world, far above those of its neighboring countries \\[Wasserman et al., 2012\\]. Suicide is the second leading cause of death among 15-24-year-olds, just after road traffic accidents, and the leading cause of death among 25-34-year-olds. Current models emphasize the variability of suicidal trajectories and the possible fluctuation in the duration of suicidal crises: for some individuals, the crisis evolves rapidly and explosively (brief), whereas for others, distress becomes more chronic, often in connection with underlying psychiatric disorders \\[Stanley, Brodsky, and Monahan, 2023\\]. In this context, the concept of a 'brief suicidal crisis' is an emerging one in psychiatry. It is characterized by an acute phase of psychological vulnerability, during which the main risk is progression to suicidal behavior, but it remains a temporary and reversible psychic crisis (lasting less than 24 hours). The crisis state is marked by a sudden inability to mobilize one's usual coping resources in the face of difficulties, making the individual highly vulnerable. Nevertheless, this concept has been little described, and a better assessment seems desirable, particularly in populations consulting a psychiatrist. Indeed, around 25% of people who die by suicide had consulted a psychiatrist in the month before their death \\[Luoma et al., 2002\\], yet few data are available on this topic.\n\nPrimary objective is to assess the prevalence of brief suicidal crisis episodes (lasting less than 24 hours) over the past 12 months among patients attending outpatient psychiatric care and within a sample of patients from a population catchment area in the Clermont-Ferrand region.",[230,27],"Suicidal Crisis",[232],"suicidal crisis","2026-07-30",{"date":235,"type":32},"2026-07-31",{"date":158,"type":23},{"date":238,"type":23},"2026-12-31",{"name":240,"class":39},"University Hospital, Clermont-Ferrand",{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":248,"targetDuration":4,"studyType":52,"phases":249,"briefSummary":250,"conditions":251,"keywords":257,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100551920","psychoeducational-course-for-suicide-prevention-100551920","NCT06466356","Psychoeducational Course for Suicide Prevention","Psychoeducational Course for Suicide Prevention - a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients with a suicide attempt, suicidal behavior, or risk of suicidal behavior and a clinician evaluating that the patient has an intention to die\n* Patients with a suicide attempt or suicidal behavior defined as \"a self-inflicted, potentially injurious behavior with a non-fatal outcome for which there is evidence of intention of death and\u002For considered to have had or been close to a suicidal crisis syndrome.\n\nExclusion Criteria:\n\n* Not being sufficiently fluent in Norwegian to provide informed consent, valid responses on psychometric testing or to benefit from a psychoeducative course.\n* A known diagnosis of ICD-10 F 60.3 (borderline personality disorder) with similar symptoms at previous admittances.\n* Ongoing psychosis.\n* A substance abuse condition to such a degree that they are unable to comply with the protocol and are considered to be at risk when attending psychoeducational courses.\n* Organic brain disorders or mental disabilities in such a degree that they are unable to comply with the protocol.\n* Not being able to give an informed consent",{"count":22,"type":23},[54],"The plan is to include patients with a history of increased risk of suicide. In the aftermath of an episode of imminent suicide risk, patients will receive a psychoeducational course that entails information on different aspects of suicide-related topics, identifying triggers and detecting early warning signals for increased suicide risk. The course culminates in working on completing a individual safety plan to prevent an future increase in suicide risk. The course will incorporate both patients and their next of kin. The psychoeducational course will be compared to a control group where the patients receive one individual session with focus on a safety plan to evaluate the intervention. Both groups will receive treatment as usual (TAU) during both the acute phase and follow-up. The study will be conducted as a randomized controlled trial.",[252,253,254,255,256,27],"Suicide Prevention","Suicide Threat","Self Efficacy","Stress, Psychological","Psychiatric Emergency",[258,259,260,261],"Psychoeducation","Safety plan","Gatekeeper","Suicidal crisis syndrome","2026-07-17",{"date":264,"type":32},"2026-07-21",{"date":266,"type":32},"2024-06-03",{"date":268,"type":23},"2031-12-31",{"name":270,"class":39},"St. Olavs Hospital",2,{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":280,"targetDuration":4,"studyType":52,"phases":282,"briefSummary":284,"conditions":285,"keywords":293,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":271},"100545041","phase-2-search-for-novel-transcranial-magnetic-stimulation-tms-targets-for-mental-illness-100545041","NCT06376734","Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness","Transdiagnostic Circuit Mapping of Prefrontal Targets in Accelerated Transcranial Magnetic Stimulation","Expedition","Inclusion Criteria:\n\n* Age 18-65\n* English proficiency sufficient for informed consent, questionnaires\u002Ftasks, and treatment\n* Primary diagnosis of one of the following: major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), or schizophrenia (determined by focal assessment using the Structured Clinical Interview for DSM-5)\n\n  * ≥20 on the Beck Depression Inventory for patients with MDD\n  * ≥16 on the Beck Anxiety Inventory for patients with GAD\n  * ≥16 on the Yale-Brown Obsessive-Compulsive Scale for patients with OCD\n  * ≥58 on the Positive and Negative Symptom Scale for patients with schizophrenia\n* Stable psychotropic medication regimen, or remain medication free, for 4 weeks prior to treatment (Medication changes during study enrollment period will be tracked for post hoc analysis).\n* Primary clinician (e.g. psychiatrist, therapist, psychologist, APRN, PA, etc.) responsible for psychiatric care before, during, and after the trial\n\nExclusion Criteria:\n\n* Active pregnancy as determined by a urine pregnancy test\n* Cluster B personality disorders (antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder)\n* PTSD with active, clinically significant symptoms, as determined by clinician\n* Diagnosis of Schizoaffective Disorder, Bipolar Type\n* Recent (within 4 weeks) or concurrent use of rapid-acting antidepressant agent (ketamine\u002Fesketamine\u002FECT)\n* Ferromagnetic metallic implant that would contraindicate receiving TMS or obtaining MRI\n* Any other TMS or MRI safety concerns identified by the clinician\n* Receiving or planning to receive other TMS treatments during course of participation\n* History of:\n\n  * Neurosurgical intervention for mental illness\n  * Moderate to severe autism spectrum disorder\n  * Intellectual disability\n  * Severe cognitive impairment\n  * Significant neurological illness (e.g., dementia, Parkinson's, Huntington's, brain tumor, seizure disorder, subdural hematoma, multiple sclerosis)\n  * Untreated or insufficiently treated endocrine disorder\n  * Eating disorders\n  * Treatment with investigational drug or intervention during the study period\n* Current evidence of:\n\n  * Mania or hypomania\n  * Active suicidal ideation or a suicide attempt within the past year\n  * Contraindications to either TMS or MRI (e.g., metallic implants, etc.).\n  * Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal\n  * Significantly increased seizure risk as determined by a clinician\n* For participants with schizophrenia:\n\n  * Evidence of impaired capacity to consent, e.g. impaired insight into illness, as deemed by a licensed psychiatrist or psychologist on the study team\n  * Hospitalization with psychosis in the past 6 months\n* Positive urine drug screen for illicit substances\n* Existing tinnitus (ringing in the ears)\n* Any other condition deemed by the PI to interfere with the study or increase risk to the participant",{"count":281,"type":23},180,[283],"PHASE2","Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.",[286,287,288,289,290,27,291,292],"Major Depressive Disorder","Obsessive-Compulsive Disorder","Schizophrenia","Generalized Anxiety Disorder","Mood Disorders","Mental Disorder","Depression, Anxiety",[294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309],"depression","anxiety","schizophrenia","OCD","obsessive-compulsive disorder","transcranial magnetic stimulation","TMS","accelerated TMS","accelerated intermittent theta burst stimulation","brain stimulation","neuromodulation","transdiagnostic","neuronavigation","functional connectivity","neuroimaging","theta burst stimulation","2026-07-14",{"date":312,"type":32},"2026-07-16",{"date":314,"type":32},"2025-01-30",{"date":316,"type":23},"2030-06-01",{"name":318,"class":39},"Brigham and Women's Hospital",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":327,"maxAge":19,"enrollmentInfo":328,"targetDuration":4,"studyType":52,"phases":330,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":40},"100549405","pilot-study-on-the-acceptability-of-auricular-vagus-nerve-neurostimulation-in-adolescents-100549405","NCT06433583","Pilot Study on the Acceptability of Auricular Vagus Nerve Neurostimulation in Adolescents","Pilot Study on the Acceptability of Auricular Vagus Nerve Neurostimulation for the Prevention of Non-suicidal Self-injury Recurrence in Adolescents","NEUROMUTE","Inclusion Criteria:\n\n* Adolescents aged between 13 and 17 years old\n* Patients with NSSI disorder as defined by DSM-5\n* Patient affiliated to a social security scheme\n* Patient who parents or guardians have signed a free and informed consent form\n* Patient able to understand neurostimulation instructions\n\nExclusion Criteria:\n\n* Contraindication to taVNS:\n* Malformation, skin pathology of the external ear. (piercings in the area concerned must be removed during the neurostimulation session).\n* Children with sleep apnea syndrome treated with NIV (non-invasive ventilation)\n* Presence of epileptic seizures\n* Proven cardiac pathology on the advice of the attending cardiologist\n* History of venous or arterial thrombosis\n* Adolescent with pacemaker or defibrillator\n* Adolescent with an active implantable device\n* Pregnancy (based on anamnestic criteria, checked by blood test if necessary)\n* Patients with psychotic episodes, confusional states or severe neurodevelopmental disorders\n* Patients with an allergic skin reaction to silicone (component of the ear electrode)\n* Patients with a cochlear implant on the stimulation side\n* Pregnant or breast-feeding women\n* Minor under guardianship\n* Minor under judicial measure or sanction","13 Years",{"count":329,"type":23},22,[54],"Non-suicidal self-injury (NSSI) are acts defined by the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders 5) as intentional and deliberate, occurring outside a psychotic state and directly causing moderate injury.\n\nTheir international prevalence is between 13 and 17% in adolescents and young adults, and has recently increased with the COVID-19 health crisis, with the prevalence of NSSI rising to 40% in adolescents. Access to psychiatrists is declining. Drug solutions, meanwhile, lack scientific proof in this indication.\n\nThe autonomic nervous system and the hypothalamo-hypophyseal axis are involved in the human response to experimentally-induced pain, as well as in stress regulation, notably via control of cortisol secretion.\n\nAbnormally low levels of the latter hormone have been detected in persons with NSSI disorder.\n\nTranscutaneous neurostimulation of the atrial vagus nerve (taVNS) has been studied for some ten years. The afferent branches of the vagus nerve stimulate the hypothalamic-pituitary axis, leading to the production of cortisol by the adrenals.\n\nThe hypothesis of this research is that stimulation of the vagus nerve by taVNS would improve the functioning of the hypothalamic-pituitary axis in patients with NSSI, and thus reduce the frequency of acting out.\n\nAlthough taVNS is an easy-to-access technique that patients can implement at home, the question of adherence to this treatment in adolescents has not yet been evaluated. The aim of this pilot study is to assess whether adolescents with NSSI will adhere to taVNS treatment.",[27],[334,335],"non-suicidal self-injury","transcutaneous auricular vagal nerve stimulation","2026-06-23",{"date":338,"type":32},"2026-06-25",{"date":340,"type":32},"2024-11-28",{"date":342,"type":23},"2027-05-28",{"name":344,"class":39},"Centre Hospitalier Régional Metz-Thionville",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":81,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":52,"phases":354,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":363,"leadSponsor":364,"locationsCount":40},"100609588","virtual-reality-viewing-of-unaltered-streetscape-versus-digitally-manipulated-opposite-streetscape-to-assess-psychosocial-response-in-participants-100609588","NCT07216534","Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants","Piloting a Virtual Reality-Based, Randomized Controlled Trial of Psychosocial Responses to Neighborhood Physical Disorder","Inclusion Criteria:\n\n* Adults 18+\n* Must currently live (4+ night\u002Fweek) at the residence being studied. Only one resident per household will be selected\n* Must understand and be able to read English\n* Must agree to have residence photographed\n* Must be able to wear a VR head mounted display\n* Must live in neighborhood that has been selected for study\n* Must be willing and able to attend an approximately 2 hour in-person visit on Ohio State University (OSU) campus\n\nExclusion Criteria:\n\n* Pregnant women\n* Visual or mobility impairment\n* Cannot have epilepsy or other condition that would inhibit them from being able to use a VR headset",{"count":353,"type":23},32,[54],"This clinical trial compares virtual reality viewing of an unaltered streetscape versus a digitally manipulated opposite streetscape to assess the psychosocial response in participants. Visible measures of neighborhood factors might be associated with health outcomes and risk factors of those outcomes. Short-term exposure to virtual reality environments representing very high or very low levels of neighborhood physical disorder - presence or absence of garbage\u002Flitter, presence or absence of graffiti, presence or absence of an abandoned building, presence or absence of large dumpsters, poor or very well-kept building conditions, poor or very well-kept yard conditions, poor or very well-kept road verge conditions may be a safe and effective way to assess psychosocial response in participants.",[357,358,27],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm","2026-06-17",{"date":361,"type":32},"2026-06-22",{"date":158,"type":23},{"date":238,"type":23},{"name":365,"class":39},"Ohio State University Comprehensive Cancer Center",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":81,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":52,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":40},"100614635","adapted-helping-ovarian-cancer-patients-cope-intervention-to-address-burnout-for-gynecologic-oncology-clinicians-100614635","NCT07282158","Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians","Adaptation of Helping Ovarian Cancer Patients Cope (HOPE) for Clinician Burnout (HOPE-C)","Inclusion Criteria:\n\n* Age 18 years of age or older\n* English speaking\n* Able to provide informed consent\n* Working with patients with ovarian cancer (gynecologic oncologists, medical oncologists, nurses, social workers, and advance practice providers \\[APPs\\])",{"count":7,"type":23},[54],"This clinical trial tests an adapted version of the Helping Ovarian Cancer Patients Cope (HOPE) intervention to address burnout among gynecologic oncology clinicians. Stress and burnout among gynecologic oncology clinicians can have far-reaching impacts not only on physicians at the individual level (e.g., distress, mental illness) but also at the professional (e.g., worse patient outcomes, increased errors) and societal levels (fewer physicians in this specialty, more system strain). The original Helping Ovarian Cancer Patients Cope (HOPE) is a workshop to promote hope among patients with ovarian cancer through creating positive narratives using the hope theory and social-cognitive theory. The adapted intervention for clinicals (HOPE-C) will use the same concepts but tailored to clinician experiences by fostering peer support and retelling their challenging stories and may address burnout for gynecologic oncology clinicians.",[377,27],"Ovarian Carcinoma","2026-06-15",{"date":359,"type":32},{"date":381,"type":32},"2026-02-24",{"date":383,"type":23},"2029-12-31",{"name":385,"class":39},"Fred Hutchinson Cancer Center",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":395,"conditions":396,"keywords":398,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":40},"100418184","neural-correlates-of-psychiatric-disorders-100418184","NCT04725409","Neural Correlates of Psychiatric Disorders","Neural Correlates of Neuropsychiatric Functions","Inclusion Criteria:\n\n* Undergoing SEEG monitoring at Vanderbilt University Medical Center\n* At least 18 years of age\n* English speaking\n\nExclusion Criteria:\n\n* Age \\\u003C18\n* Not able to complete questionnaires (e.g., unable to comprehend instructions or follow directions)",{"count":394,"type":23},100,"This ClincialTrials.gov record originally corresponded to the protocol approved under IRB # 202370. The study was expanded to include stimulation and recordings approved under new IRB #211037. The participant data originally acquired from IRB# 202370 will be included in this new record:\n\nThis study seeks to better understand the neural activity underlying neuro cognitive disorders. Resting state local field potential recordings will be collected from medically refractory epilepsy patients implanted with depth electrodes for seizure localization, and metrics of neural activity will be correlated with psychiatric symptoms as measured from questionnaires. Subjects will also participate in neuro cognitive tasks while neural recordings are performed, and\u002For receive neural stimulation through implanted depth electrodes. A better understanding of disordered neural activity underlying neuropsychiatric disorders may additionally contribute to novel methods for diagnosing, treating, and preventing these diseases.",[27,397],"Memory Disorders",[399,400,401,402,403,404],"Depression","Stereo Electroencephalography (SEEG)","Anxiety","Obsessive compulsive disorder","Impulsivity","Memory","2026-06-10",{"date":407,"type":32},"2026-06-12",{"date":409,"type":32},"2021-03-31",{"date":411,"type":23},"2027-12",{"name":413,"class":39},"Vanderbilt University Medical Center",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":52,"phases":422,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":40},"100597023","external-facilitation-to-increase-prescribing-of-aud-medications-in-the-psychiatric-setting-100597023","NCT07053098","External Facilitation to Increase Prescribing of AUD Medications in the Psychiatric Setting","Inclusion Criteria:\n\n* For prescribers: working as a prescriber, non-prescribing clinician, or administrator at one of the three participating clinics.\n* For patients: has major mental illness (major depressive disorders, bipolar disorder, schizophrenia spectrum disorders, other psychotic disorders; posttraumatic stress disorder)\n* For patients: has Alcohol Use Disorder and is being treated in one of the three participating clinics.\n\nExclusion Criteria:\n\n* For all: age is less than 18 years old\n* For all: not able to complete informed consent","90 Years",{"count":173,"type":23},[54],"This project will pilot test an implementation facilitation intervention to increase prescribing of medications for alcohol use disorder (MAUD) in patients with major mental illness and alcohol use disorder in three psychiatry treatment clinics.",[425,27],"Alcohol-Related Disorders","2026-05-29",{"date":428,"type":32},"2026-06-03",{"date":430,"type":32},"2025-03-18",{"date":432,"type":23},"2027-05-31",{"name":434,"class":39},"University of Maryland, Baltimore",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":81,"sex":18,"minAge":4,"maxAge":19,"enrollmentInfo":441,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":271},"100387284","transgenerational-metabolic-immune-biomarkers-of-neurological-and-neurodevelopmental-disorders-100387284","NCT04322734","Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders","Inclusion Criteria (ASD):\n\n1. ASD, as defined by either a gold standard measure for ASD diagnosis, the Autism Diagnostic Observation Schedule (ADOS); the Autism Diagnostic Interview-Revised (ADI-R); and\u002For a comprehensive assessment that is consistent with ASD, in the opinion of the principal investigator. For those the PI believes a prospective diagnosis of ASD is warranted, a formal diagnostic assessment will be scheduled at screening.\n2. 0 years through 17 years 11 months of age\n\nInclusion Criteria (TD, MD, Epilepsy, Brain Tumor, Psychiatric)\n\n1\\. 0 years to 17 years 11 months of age\n\nExclusion Criteria (All):\n\n1. History of a significant adverse reaction to a prior blood draw\n2. In females of reproductive age, pregnancy or plans to become pregnant\n3. Any other historical event\u002Finformation that may, in the opinion of the PI, be a reason to exclude the child from participation.",{"count":442,"type":23},500,"The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and\u002For questionnaires. Other samples may be collected when appropriate.\n\nThis study is currently recruiting.\n\nThere is no cost for visits or study-related exams.",[445,446,447,448,27,449],"Autism Spectrum Disorder","Mitochondrial Pathology","Epilepsy","Brain Tumor","Mitochondrial Diseases","2026-04-22",{"date":452,"type":32},"2026-04-23",{"date":454,"type":32},"2023-12-13",{"date":456,"type":23},"2028-12-31",{"name":458,"class":39},"Southwest Autism Research & Resource Center",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":465,"targetDuration":4,"studyType":52,"phases":467,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":40},"100513204","phase-1-hnc-human-neural-circuits-electrophysiology-during-cognition-100513204","NCT05962424","HNC: Human Neural Circuits Electrophysiology During Cognition","Inclusion Criteria:\n\n* Patient in clinical neuro inpatient units at Stanford Medical Center\n* Age \\>18 years old\n* Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex)\n\nExclusion Criteria:\n\n* Lifetime psychotic disorder\n* Pregnant or nursing females\n* Prior adverse ketamine response\n* Use of ketamine in past 7 days",{"count":466,"type":23},120,[468],"PHASE1","The purpose of this study is to understand how ketamine brings about dissociative symptoms.",[27],"2026-04-21",{"date":450,"type":32},{"date":474,"type":32},"2023-10-05",{"date":476,"type":23},"2030-09-01",{"name":478,"class":39},"Stanford University",{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":18,"minAge":486,"maxAge":20,"enrollmentInfo":487,"targetDuration":4,"studyType":52,"phases":489,"briefSummary":490,"conditions":491,"keywords":494,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":40},"100572862","evaluation-of-the-efficiency-of-the-prpp-perceive-recall-plan-and-perform-task-analysis-system-on-support-and-orientation-decisions-for-people-with-aging-psychiatric-disorders-patpv-living-in-independent-housing-100572862","NCT06738784","Evaluation of the Efficiency of the PRPP (Perceive, Recall, Plan and Perform) Task Analysis System on Support and Orientation Decisions for People With Aging Psychiatric Disorders (PATPV) Living in Independent Housing.","ECO2PSY","Inclusion Criteria:\n\n* Be at least 40 years old\n* Reside within the PGU sector (Mérignac, Pessac, Talence and Gradignan)\n* Receive support from the PGU - CHCP \"pathologies, disability and aging\" department.\n* Fluency in French\n\nExclusion Criteria:\n\n* Being hospitalized for more than 18 months\n* Refuse inclusion in the research project","40 Years",{"count":488,"type":23},66,[54],"Over the past 30 years, mental health policy has been geared towards increasing the number of people receiving care in the community, with a reduction of over 50% in the number of general psychiatric beds. The WHO recommends the implementation of alternatives to hospitalization, through the development of outpatient and home-based psychiatric care programs that support independent living.\n\nPeople suffering from psychiatric disorders show cognitive decline as they age, including deficits in perception, attention, memory and problem-solving. These cognitive problems affect the ability to carry out the tasks of daily life, and make it more difficult to remain at home. In order to avoid hospitalization for these psychiatrically-stabilized patients who are losing their autonomy, it is necessary to take into account their mental and cognitive handicap, and to provide them with appropriate compensation.\n\nOccupational therapy is a discipline concerned with the assessment, rehabilitation and integration of people with disabilities. Occupational therapists provide ecological assessments to support personalized care plans. The PRPP (Perceive, Recall, Plan and Perform) task analysis system is a validated, ecological tool that integrates an occupational therapy assessment and intervention model. The PRPP assessment measures occupational performance and the impact of cognitive impairments on information processing and on the cognitive strategies required to carry out activities. Research conducted in Canada illustrates the value of PRPP in supporting people with schizophrenia. To the best of our knowledge, no team has studied the use of PRPP in the decision-making process for maintaining people with aging psychiatric disorders (PATPV) at home.",[492,493,27],"Mental Health","Aging Disorder",[495,496,497],"mental health","geriatric psychiatry","ergotherapy","2026-03-13",{"date":500,"type":32},"2026-03-16",{"date":502,"type":32},"2024-12-09",{"date":504,"type":23},"2027-12-31",{"name":506,"class":507},"Centre Hospitalier Charles Perrens, Bordeaux","OTHER_GOV",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":516,"targetDuration":4,"studyType":52,"phases":518,"briefSummary":519,"conditions":520,"keywords":524,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":536,"locationsCount":40},"100337803","treating-depression-on-a-day-to-day-basis-development-of-a-tool-for-physicians-based-on-a-smartphone-application-100337803","NCT03678194","Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application","Treating Depression on a Day-to-day Basis: Development of a Novel Clinical Tool for Physicians Based on a Smartphone Application, the SMART Project (Smartphones and Mood Disorders, an Application for Research and Treatment)","SMART","Inclusion Criteria:\n\n* Age between 18 and 65 years;\n* Fulfilling the Diagnostic and Statistical Manual version IV (DSM-IV) criteria of depression assessed by the Structured Clinical Interview;\n* Patients started their antidepressant treatment less than 5 days before inclusion;\n* Patient treated in an outpatient setting;\n* Patient informed of the diagnosis of his disease;\n* Informed patient with written consent.\n\nExclusion Criteria:\n\n* A current mental or psychiatric impairment or disease (schizophrenia, bipolar disorder) that required psychotropic medication or inpatient treatment on a psychiatric ward;\n* A history of psychosis, including schizophrenia, bipolar I or bipolar II disorder, and major depressive disorder with psychotic features;\n* Cognitive deficit and not thus being able to comprehend the informed consent and study procedure;\n* Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….);\n* Non-comprehension of the French language",{"count":517,"type":23},200,[54],"Testing and validating an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care.",[399,27,521,522,523],"Brain Diseases","Central Nervous System Diseases","Nervous System Diseases",[399,525,526,527,528,529,530,531],"Smartphone","Relapse prevention","Mobile support system","eHealth","Ecological","Randomized","Multicentric",{"date":500,"type":32},{"date":534,"type":32},"2020-10-14",{"date":238,"type":23},{"name":506,"class":507},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":544,"minAge":19,"maxAge":545,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":40},"100508189","investigating-the-pathophysiological-nature-of-homosexuality-100508189","NCT05897177","Investigating the Pathophysiological Nature of Homosexuality","Investigating the Pathophysiological Nature of Homosexuality Patients in Egypt, England, China, and Mexico: Multicenter Study.","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Male will be included\n\nExclusion Criteria:\n\n* Patients taking testosterone or its derivative.\n* Patients taking anabolic steroids.\n* Multi-sexual behaviours.\n* HIV patients.\n* not having and addictive disorder","MALE","60 Years",{"count":442,"type":23},"Debate continues on whether or not male homosexuality (MH) is a result of biological or cultural factors. The debate persists despite the fact that these two sides have different abilities to create a scientific environment to support their cause. Biological theorists produced evidence, however, that these are not always robust. On the other hand, social theorists, without direct evidence confirming their positions, criticize, with good argument, methods and results of the other side.",[27],"2026-03-12",{"date":500,"type":32},{"date":552,"type":32},"2023-07-20",{"date":554,"type":23},"2028-04-20",{"name":556,"class":39},"Mostafa Bahaa",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":81,"sex":18,"minAge":19,"maxAge":171,"enrollmentInfo":564,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":4},"100624167","meop---multidimensional-evaluations-in-oncological-psychiatry-100624167","NCT07406113","MEOP - Multidimensional Evaluations in Oncological Psychiatry","MEOP","Inclusion Criteria:\n\n* For cases: any subject affected by cancer with a comorbid psychiatric disorder (further defined as \"cases\") or any first-degree relative of a subject of a \"case\" (i.e., i.e. a fist-degree relative of a subject affected by cancer and a psychiatric disorder). These first-degree relatives will be defined as \"cases-rel\".\n* For controls: a) Subjects with cancer who will undergo a consultation in the Clinical and Emergency Psychiatry Unit of the Fondazione Policlinico Universitario Agostino Gemelli IRCCS but who do not show any psychiatric symptoms (further defined as \"oncology-controls\"); b) subjects without cancer who will undergo a psychiatric evaluation in the Clinical and Emergency Psychiatry Unit and present psychiatric symptoms (further defined as \"psy-controls\"); c) Subjects without cancer and with any suspected psychiatric disorder who will undergo a psychiatric evaluation in the Clinical and Emergency Psychiatry Unit and who are not diagnosed with any relevant psychiatric symptoms after the evaluation (further defined as \"healthy controls\"); d) First-degree relatives of \"oncology-controls\", \"psy-controls\" and \"healthy controls\" (further defined as \"control-rel\").\n* Age between 18 and 75 years.\n* Capability of providing written informed consent.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or inability to provide written informed consent.\n* Severe unstable neurological disorders, such as traumatic brain injury, Alzheimer's Disease or dementia.\n* Inability to perform psychiatric or neuropsychological evaluations.",{"count":565,"type":23},2000,"Cancer is among the leading causes of morbidity and mortality worldwide, profoundly affecting patients' lives at every level, and its psychological and psychiatric impacts remain a major concern. Psychiatric disorders are frequently observed in cancer patients. Nevertheless, they were also underdiagnosed, with a consequent undermining possible interventions. Still, psychiatric disorders in cancer patients are not merely secondary complications but may actively contribute to poor oncological outcomes.\n\nThe pathophysiology of cancer-related psychiatric disorders is multifactorial and is related to several neuropsychological and neurobiological factors. Specifically, the production of cytokines associated with cancer appears to play a role in the development of depression. Tumours trigger an inflammatory response that leads to the release of pro-inflammatory cytokines. These cytokines influence central nervous system function and disrupt the regulation of the HPA axis, contributing to psychological symptoms such as depression, fatigue, sleep disturbances, and appetite loss.\n\nMoreover, psychiatric symptoms in cancer patients are often accompanied by neuropsychological alterations including deficits in memory, executive function, and attention. Compared to other individuals with psychiatric disorders, cancer patients may experience more severe cognitive impairments which can be exacerbated by cancer treatments, including surgery, chemotherapy, and radiotherapy. These treatments stimulate cytokine production by nearby non-cancerous cells and immune cells activated in response to treatment-induced cell death, thereby driving systemic inflammation.\n\nCancer profoundly affects not only patients but also their families, who often bear the emotional and caregiving burden. Being close to a loved one with cancer can lead to significant psychological distress, including anxiety and depression, among family members and caregivers. The ripple effects of this burden underscore the need for a holistic approach to mental health in oncology.\n\nGiven the background presented so far, identifying and managing psychiatric comorbidities in oncological patients and their families is crucial. This multifaceted interplay between cancer and psychiatric disorders necessitates a comprehensive, interdisciplinary approach to understanding, diagnosing, and treating these conditions effectively.",[27,568,569,570,571],"Cognition Disorder","Treatment Compliance","Adverse Drug Event","Family Members","2026-02-09",{"date":574,"type":32},"2026-02-12",{"date":576,"type":23},"2026-01-30",{"date":578,"type":23},"2036-01-29",{"name":580,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":52,"phases":589,"briefSummary":590,"conditions":591,"keywords":592,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":600,"locationsCount":40},"100539478","braining---evaluation-of-acute-effects-of-physical-exercise-100539478","NCT06304363","Braining - Evaluation of Acute Effects of Physical Exercise","Braining Study - Physical Exercise in Psychiatry - Evaluation of Acute Effects","Inclusion Criteria:\n\n* Included in the retrospective study Physical Exercise as Adjunctive Therapy for Affective Disorder and Anxiety and has given informed consent to participation in a Braining booster session.\n\nExclusion Criteria:\n\n* Severe psychiatric disorder such as mania and psychosis\n* Medical conditions such as heart- and lung diseases where PE is contraindicated.\n* Unable to understand written and spoken Swedish language.",{"count":196,"type":23},[54],"\"Braining\" is a clinical method for physical exercise as adjunctive therapy in psychiatric care. The core components are personnel-led group training sessions and motivating contact with psychiatric staff, as well as measurements and evaluations before and after a training period.\n\nThe scientific purpose of this study is to investigate immediate and short-term effects of a booster-session of several Braining classes.",[27],[593,594],"Psychiatric disorder","Physical Exercise",{"date":596,"type":32},"2026-02-06",{"date":598,"type":23},"2028-01-01",{"date":383,"type":23},{"name":601,"class":507},"Region Stockholm",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":4,"eligibilityCriteria":608,"healthyVolunteers":81,"sex":18,"minAge":609,"maxAge":4,"enrollmentInfo":610,"targetDuration":612,"studyType":24,"phases":4,"briefSummary":613,"conditions":614,"keywords":658,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":681,"lastUpdatePostDateStruct":682,"startDateStruct":684,"completionDateStruct":686,"leadSponsor":688,"locationsCount":40},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417","NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform","2 Years",{"count":611,"type":23},10000,"10 Years","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,27,656,657],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[635,659,660,661,662,663,664,665,666,667,616,668,669,670,671,672,637,673,674,675,676,677,678,679,680],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","2026-01-20",{"date":683,"type":32},"2026-01-22",{"date":685,"type":32},"2023-07-05",{"date":687,"type":23},"2030-12-31",{"name":689,"class":39},"Brain Inflammation Collaborative",{"id":691,"slug":692,"hasResults":12,"nctId":693,"briefTitle":694,"officialTitle":694,"acronym":695,"eligibilityCriteria":696,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":697,"targetDuration":4,"studyType":52,"phases":698,"briefSummary":699,"conditions":700,"keywords":701,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":705,"lastUpdatePostDateStruct":706,"startDateStruct":708,"completionDateStruct":710,"leadSponsor":711,"locationsCount":271},"100620208","full-sail-ahead-sailing-in-psychosocial-rehabilitation-100620208","NCT07354633","Full Sail Ahead, Sailing in Psychosocial Rehabilitation.","VOILE_RPS93","Inclusion Criteria:\n\n* Obtaining free and informed consent to the research project\n* User over 18 years old and living in the 93\n* Living with a psychic or neurodevelopmental disorder\n* Supported by the RPS 93 platform\n* Have obtained a medical certificate of fitness for sailing including competition (only for the sailing group)\n* Knowing French language ( how to read and write)\n* Clinical condition stabilized for less than three months despite taking medication\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Psychiatric decompensation",{"count":173,"type":23},[54],"This study is part of the desire to develop disabled sports in the territory of Seine-Saint-Denis and responds to the national strategy plan Sport Santé, 2019-2024, which addresses all audiences. The law of January 26, 2016 recognizes sport as a non-drug therapeutic in its own right, becoming an element of the hospital care pathway but also ambulatory. The partnership between the EPS of Ville-Evrard and the departmental committee of Voile du 93, co-funder of the project thus allows the diversification and the increase of the offer of care in psychosocial rehabilitation.",[27],[702,703,704],"Sailing","psychiatric disorder","physical conditions","2026-01-12",{"date":707,"type":32},"2026-01-21",{"date":709,"type":32},"2025-09-01",{"date":456,"type":23},{"name":712,"class":39},"Centre hospitalier de Ville-Evrard, France",{"id":714,"slug":715,"hasResults":12,"nctId":716,"briefTitle":717,"officialTitle":718,"acronym":719,"eligibilityCriteria":720,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":721,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":723,"conditions":724,"keywords":725,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":729,"lastUpdatePostDateStruct":730,"startDateStruct":732,"completionDateStruct":734,"leadSponsor":736,"locationsCount":40},"100617343","group-psychoeducation-to-promote-independent-living-in-individuals-with-psychiatric-disorders-100617343","NCT07317388","Group Psychoeducation to Promote Independent Living in Individuals With Psychiatric Disorders","Study on the Effectiveness of Group Psychoeducation (for Users and Caregivers) in Promoting Autonomy at Home for Individuals With Psychatric Disorder.","AUTON'HOME","Inclusion Criteria:\n\n* Volunteer for a home autonomy project\n* Management of a mental health problem (mood disorder or psychotic disorder)\n* Consent for participation (non-opposition)\n* Taken care by the RPS 93 platform\n\nExclusion Criteria:\n\n* Acute clinical state",{"count":722,"type":23},24,"This study evaluates the effectiveness of group psychoeducation for users and carers to help people with severe psychiatric disorders achieve autonomy at home.",[27],[205,726,495,727,728],"autonomy","group therapy","independent living","2025-12-19",{"date":731,"type":32},"2026-01-05",{"date":733,"type":32},"2025-05-01",{"date":735,"type":23},"2027-02",{"name":712,"class":39},{"id":738,"slug":739,"hasResults":12,"nctId":740,"briefTitle":741,"officialTitle":742,"acronym":4,"eligibilityCriteria":743,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":744,"enrollmentInfo":745,"targetDuration":4,"studyType":52,"phases":746,"briefSummary":748,"conditions":749,"keywords":752,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":755,"lastUpdatePostDateStruct":756,"startDateStruct":758,"completionDateStruct":760,"leadSponsor":762,"locationsCount":40},"100557125","phase-4-transcranial-magnetic-stimulation-for-nicotine-dependence-an-effectiveness-implementation-trial-100557125","NCT06534047","Transcranial Magnetic Stimulation for Nicotine Dependence: An Effectiveness-Implementation Trial","Integrating Transcranial Magnetic Stimulation as a Treatment for Nicotine Dependence in the Clinic: A Pragmatic, Hybrid Effectiveness-Implementation Trial","Inclusion Criteria:\n\nPatient Participants:\n\nThe patient participant must meet all the inclusion criteria to be eligible for this study:\n\n1. Able to provide informed consent.\n2. Age 18-70.\n3. Self-reported daily tobacco cigarette consumption.\n4. Meet DSM-5 criteria for a psychiatric disorder that includes one of the following: mood disorders (e.g. major depressive disorder, bipolar disorder), anxiety disorders (e.g. panic disorder, social anxiety disorder), psychotic disorders (e.g. schizophrenia), posttraumatic stress disorder, obsessive compulsive disorders, or other substance use disorders (e.g. alcohol use disorder) as determined by the Structured Clinical Interview for DSM-5 Disorders, Research Version (SCID-5 RV).\n5. Interested in using either Repetitive Transcranial Magnetic Stimulation (rTMS) or nicotine replacement therapy as a smoking cessation treatment.\n6. Intending on quitting smoking within the next 30 days.\n\nExclusion Criteria:\n\nPatient Participants:\n\n1. Contraindication to rTMS according to the TMS Adult Safety Screen (TASS) and PI review.\n2. Have any intracranial implant (e.g., aneurysm clips) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed.\n3. Pregnant or intending to be pregnant during the study.\n4. A history of a primary seizure disorder, seizure associated with an intracranial lesion, recurrent seizures related to substance intoxication or withdrawal or recent seizure within the last 6 months.\n5. Space occupying intracranial lesion.\n6. Any generalized skin disorders precluding the use of the nicotine patch.\n7. Any known hypersensitivity or allergies to the nicotine patch.\n8. Any known life-threatening arrhythmias or severe\u002Fworsening angina pectoris.\n9. Within two weeks of experiencing a myocardial infarction or cerebral vascular accident.\n10. Currently using or has used nicotine replacement therapy within the past two weeks.\n11. Diagnosed with a terminal illness\n12. Current regular use of e-cigarettes or other vaping devices containing nicotine and not willing to stop using these devices for the duration of the study.\n13. Acutely unstable medical, psychiatric, or substance use disorder comorbidity with safety concerns at the discretion of the PI or study physician.\n14. Previous treatment with rTMS for smoking cessation\n15. Treatment with nicotine replacement therapy anytime within the last 1 month","70 Years",{"count":173,"type":23},[747],"PHASE4","Tobacco smoking is the leading preventable cause of morbidity and mortality worldwide. However, currently available treatments, including standard pharmacotherapy and behavioural support, are limited in their efficacy, tolerability, and acceptability by patients. Additionally, tobacco use is substantially higher in individuals with comorbid mental illness, constituting a particularly vulnerable population. As such, the development of multiple evidence-based treatments for smoking cessation is of upmost importance.\n\nRepetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain-based approach in which alternating magnetic fields are applied to the scalp to induce electrical currents in cortical tissue. As it can modulate neural circuits implicated in neuropsychiatric disorders, it is a promising brain-based approach in the treatment of substance use disorders. Recently, a deep TMS coil has been cleared by the Food and Drug Administration (FDA) as efficacious for tobacco use disorder, representing the first rTMS indication for addictions. Before adoption of this intervention into smoking cessation clinics, it is important to investigate whether implementation of rTMS into clinical care is feasible, acceptable, and appropriate for patients receiving care for nicotine dependence.\n\nThe objective of this study is to compare the effectiveness of rTMS versus treatment as usual for patients with psychiatric disorders seeking treatment for smoking cessation. Also, barriers to the implementation of rTMS in routine clinical care will be examined by speaking with patients and health care providers on their experience with rTMS.",[750,27,751],"Tobacco Use Disorder","Nicotine Dependence",[753,751,754],"Repetitive Transcranial Magnetic Stimulation","Smoking Cessation","2025-12-05",{"date":757,"type":32},"2025-12-11",{"date":759,"type":32},"2024-09-01",{"date":761,"type":23},"2026-12-01",{"name":763,"class":39},"Centre for Addiction and Mental Health",{"id":765,"slug":766,"hasResults":12,"nctId":767,"briefTitle":768,"officialTitle":769,"acronym":770,"eligibilityCriteria":771,"healthyVolunteers":81,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":772,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":773,"conditions":774,"keywords":777,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":781,"lastUpdatePostDateStruct":782,"startDateStruct":784,"completionDateStruct":786,"leadSponsor":788,"locationsCount":40},"100377229","investigating-neural-response-variability-as-a-single-patient-predictor-of-successful-cbt-in-clinical-psychiatry-100377229","NCT04191811","Investigating Neural Response Variability as a Single-patient Predictor of Successful CBT in Clinical Psychiatry","Moment-to-moment Neural Variability as a Predictor of Treatment Outcome in Patients With Common Psychiatric Disorders: Major Depressive Disorder, Insomnia and Social Anxiety Disorder","TreVar","Inclusion Criteria:\n\n* Meeting DSM-5 criteria for depression, social anxiety or insomnia. Diagnosis and measures of symptom burden and functional level are made through a structured interview, the Mini-International Neuropsychiatric Interview (M.I.N.I.) and self-assessments of symptoms. Healthy controls should not be relevant to psychiatric treatment nor meet criteria for any psychiatric condition according to the M.I.N.I.\n* Being able to read, write and speak Swedish in order to be able to read the treatment texts and be able to make phone calls.\n* Having basic computer skills to be able to complete surveys via the Internet and access the treatment platform.\n\nExclusion Criteria:\n\n* Physical or mental illnesses who are either contraindicated for treatment (for example, bipolar disorder that can be exacerbated by treatment) or for other reasons need other treatments (e.g. severe depression, suicidal behavior, psychotic illnesses or extensive cognitive difficulties).\n* High alcohol consumption or other ongoing drug use.\n* Answering \"yes\" to any of the following questions will be excluded for participation: 1) \"Have you or have you had any electrical \u002F battery operated implants in your body? For example, a pacemaker, medication pump, neurostimulator, hearing implant, or other electrical \u002F battery controlled implant?\" 2) \"Have you done any surgery on the abdomen, chest, heart or brain, eyes, ears? For example, vessel clips, or objects such as screws, heart valve, shunt or prosthesis?\" 3) \"Do you have or have you had any metallic object in your body?\" 4) \"If a woman, are you pregnant or breastfeeding?\" 5) \"Do you undergo dialysis or have kidney dysfunction?\" Participants who answer yes to these follow-up questions will be interviewed more closely to determine if MRI security can be guaranteed and whether the MRI signal will have significant disruptions, for example due to dental scaffolding. 1) \"If you have any abdominal, thoracic, heart or brain, eyes, ears? Do you have any inoperable object that has ferromagnetic properties?\" The patient will be asked to consult his doctor about this. 2) \"If you have a dental rack, what type of dental rack (fixed or removable, metal plates \u002F rails or wire)\"?",{"count":226,"type":23},"Many psychiatric patients are not sufficiently improved by current interventions. Functional magnetic imaging brain imaging (fMRI) has proven to be a promising method for predicting treatment outcomes in psychiatric treatment. Individuals moment-to-moment variability have not yet been evaluated as a predictor of treatment of three common forms of mental illness: depression, insomnia and health anxiety. The goal is to investigate whether objective measurements of brain function contribute to a better prediction of a patient's success in treatment than experiences and self-reports, e.g., treatment credibility and patients expectations about the treatment. The prediction model will be tested on internet-delivered CBT (iCBT) for depression, insomnia and social anxiety. Patients in each diagnostic group are asked for participation before treatment. The total number of participants in this study will amount to 225 participants. The goal is that 35% consists of healthy controls and that the remaining part is equally distributed between the three diagnostic patient groups.\n\nBeing able to better predict how well a psychiatric treatment will work for an individual has great value from both an economic and a treatment perspective. The findings from this study may contribute to increased knowledge about neurobiological complications in mental illness. In the longer term, it can lead to improved routines and help in clinical decision-making when patients should be recommended treatment.",[27,399,775,776],"Anxiety Disorders","Insomnia",[778,779,780],"Internet-delivered Cognitive Behavior Therapy","BOLD-fMRI","Moment-to-moment variability","2025-10-01",{"date":783,"type":32},"2025-10-07",{"date":785,"type":32},"2022-04-01",{"date":787,"type":23},"2026-01",{"name":789,"class":39},"Karolinska Institutet"]